Biogen Halts Plans to Develop Tysabri for Stroke After Phase IIb Trial Flop Post author:Sam Post published:February 6, 2018 Post category:BioPharma Natalizumab did not demonstrate improvement in clinical outcomes compared to placebo. Source: BioSpace You Might Also Like Sumitomo Dainippon Pharma, Poxel Ink $300M Diabetes Pact October 29, 2017 MilliporeSigma Opens China's First BioReliance End-to-End Biodevelopment Center In Shanghai September 21, 2017 Akari CEO Abruptly Steps Down Amid Investigation Into Phase II Trial Data May 30, 2017
MilliporeSigma Opens China's First BioReliance End-to-End Biodevelopment Center In Shanghai September 21, 2017